Fulcrum Therapeutics (FULC) EBT (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported EBT for 9 consecutive years, with -$35.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, EBT rose 16.65% year-over-year to -$35.0 million; the TTM figure through Jun 2026 stood at -$234.1 million (down 78.59% YoY), while the FY2025 annual figure was -$161.2 million, down 119.71% from the prior year.
• EBT grew to -$35.0 million in Q2 2026 per FULC's latest filing, from -$50.0 million in the prior quarter.
• Across five years, EBT topped out at $40.2 million in Q2 2024 and bottomed at -$94.0 million in Q1 2022.
• Historically, EBT has averaged -$42.8 million across 5 years, with a median of -$41.6 million in 2023.
• Annual changes were most pronounced in 2024 — EBT soared 197.39% — and 2025, when it slumped 236.18%.
• Fulcrum Therapeutics' EBT stood at -$29.9 million in 2022, then slumped by 44.37% to -$43.1 million in 2023, then soared by 41.93% to -$25.0 million in 2024, then plunged by 236.18% to -$84.2 million in 2025, then soared by 58.43% to -$35.0 million in 2026.
• Business Quant data shows FULC's EBT at -$35.0 million in Q2 2026, -$50.0 million in Q1 2026, and -$84.2 million in Q4 2025.